Schedule III is half official. On April 22, Acting AG Todd Blanche signed a thirty-four-page order rescheduling FDA-approved marijuana and state medical cannabis under treaty authority. The rest of cannabis gets a six-week hearing in Arlington. The industry is toasting a meal that was never served. What AG Order 6754-2026 actually did, what it didn't, and what cannabis testing labs should be doing this week before federal scrutiny arrives with a return address.

Novo Nordisk found the problem themselves. Opened a deviation. Identified the root cause. Documented the corrective actions. Then closed it without confirming anything was fixed. FDA showed up and found the same problem still running. This isn't a Novo Nordisk story — it's a QMS story.

Most laboratories don’t fail audits in the conference room.
They fail quietly, weeks or months earlier, when systems drift, assumptions accumulate, and defensibility erodes unnoticed.

Passing an audit may confirm compliance at a moment in time, but it does not guarantee that documentation, data integrity, or governance would hold up under deeper scrutiny. This article explores where audit failures actually begin, why “fixing findings” rarely reduces risk, and how regulatory gap analysis creates clarity before pressure forces the issue.

Trump didn’t legalize cannabis. He revived a stalled rescheduling process and took the victory lap. Schedule III changes the optics, not the fundamentals; and it puts laboratories and operators on a collision course with federal scrutiny they’re not prepared for.

Most laboratories don’t fail audits because of cyberattacks. They fail because data integrity can’t be proven after routine system failures, restores, or IT fixes.